# 克睿基因 Cure Genetics

> 克睿基因 Cure Genetics is a clinical-stage biotech founded in Suzhou in 2016 that develops cell and gene therapies for solid tumors and genetic diseases. It runs two proprietary platforms: AIMS, an allogeneic CAR-NKT cell therapy approach aimed at hard-to-treat solid tumors, and VELP, a directed-evolution AAV vector platform that builds high-quality viral libraries for tissue-targeted gene delivery to the nervous system, heart, and kidney. Its lead programs include CGC729 (anti-CD70 CAR-NKT for renal cell carcinoma) and CGC-602 (a PD-1-IL-2v bispecific antibody).

- **Founded:** 2016
- **Headquarters:** Suzhou, China
- **Founders:** Yuanyuan Xu (Co-Founder, Chairman & CEO)
- **Team size:** Reported variously: ~13 (Apollo) to 100-200 (LinkedIn/SignalHire)
- **Products:** AIMS CAR-NKT Platform, VELP AAV Vector Platform, CGC729, CGC-602, Molecular diagnostics / gene editing tools
- **Notable:** Presented interim Phase I CAR-NKT data for renal cell carcinoma at the 27th ASGCT Annual Meeting, Unveiled research at the 2024 ASGCT Annual Meeting, Closed a $60M Series B in February 2022

## Products & services

- **AIMS CAR-NKT Platform** — An allogeneic cell therapy platform that engineers invariant natural killer T (NKT) cells with chimeric antigen receptors to target solid tumors, with a focus on tumor infiltration and modulating the tumor microenvironment.
- **VELP AAV Vector Platform** — A proprietary directed-evolution gene therapy platform that constructs high-quality viral libraries and uses in vivo screening to develop AAV capsids/serotypes for tissue-targeted delivery to the nervous system, heart, and kidney.
- **CGC729** — An anti-CD70 CAR-NKT cell therapy candidate in Phase I for relapsed/refractory metastatic renal cell carcinoma (RCC).
- **CGC-602** — A PD-1-IL-2v bispecific antibody candidate for cancer immunotherapy.
- **Molecular diagnostics / gene editing tools** — Applications of CRISPR-based gene editing and DNA enrichment-RNA detection technology for molecular diagnostics and research.

## Achievements

- Presented interim Phase I CAR-NKT data for renal cell carcinoma at the 27th ASGCT Annual Meeting
- Unveiled research at the 2024 ASGCT Annual Meeting
- Closed a $60M Series B in February 2022
- Built two distinct clinical-stage platforms (CAR-NKT cell therapy and VELP AAV gene therapy)
- Recruited senior cell-therapy leaders including a CTO with 20+ years of global experience

## Latest updates

- **2024-05** — Presented CAR-NKT interim renal cell carcinoma data in an oral presentation at the 27th ASGCT Annual Meeting.
- **2024-01** — Announced upcoming achievements to be unveiled at the 2024 ASGCT Annual Meeting.
- **2023-08** — Strengthened leadership: appointed Dr. Ren Li as CTO of Cell Therapy, Dr. Shawn He as CSO of Cell Therapy, and Dr. Pengcheng Zhou as VP of Gene Therapy R&D.
- **2022-02** — Completed $60M Series B financing led by Advantech Capital.

## Links

- Website: https://curegenetics.com
- LinkedIn: https://www.linkedin.com/company/curegenetics

---

Profile page: https://yespress.io/cure-genetics
Published by YesPress — https://yespress.io
Last updated: 2026-06-15